12:00 AM
 | 
May 31, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Prolia denosumab regulatory update

The European Commission approved Prolia denosumab from Amgen to treat osteoporosis in postmenopausal women at increased risk of fractures and to treat bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Amgen said this is the first approval worldwide of...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >